Tenax Therapeutics, Inc. announced the appointment of Paula Bokesch, M.D. as Chief Medical Officer, effective February 14, 2015. In addition, Dr. Bokesch will direct clinical development for the company's lead asset, levosimendan, including the current Phase 3 LEVO-CTS trial to evaluate the use of levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). Dr. Bokesch has more than 10 years of drug development experience in acute and critical care indications.

Most recently she worked for 5 years as a Senior Medical Director for Drug Development at Cubist Pharmaceuticals, where she served within the Company's programs for Daptomycin, pain, acute/critical care and antibiotics. Dr. Bokesch also served as Global Medical Director for Hospira, where she worked in Medical Affairs and Drug Development within the Precedex and acute/critical care programs.